ProvideGx to hike production of 5 generic injectables in short supply

ProvideGx, a subsidiary of Premier, will collaborate with Fresenius Kabi to help mitigate national shortages of five generic injectable medications.

The two companies will boost production of injectable thiamine, lidocaine, diphenhydramine, hydromorphone and morphine sulfate.

ProvideGx was established by Premier in January to address supply shortages plaguing health systems across the U.S.

The company plans to work with generic drug manufacturers, co-fund development of affordable products and secure contracts for active pharmaceutical ingredients to ensure supply demands are met. ProvideGx will begin with drugs from a target list of more than 60 that are in short supply.

The financial terms of the collaboration with Fresenius were not disclosed.

More articles on pharmacy:
8 recent pharmaceutical lawsuits, settlements
McKesson renews distribution deal with CVS Health
Sacklers discussed selling Purdue Pharma in 2000, court documents reveal

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers